Additional consideration contract with customer liability.

No definition available.

Name:	rptx_AdditionalConsiderationContractWithCustomerLiability
Namespace Prefix:	rptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amoun t of collaboration revenue receivable

+ References

No definition available.

+ Details

Name:	rptx_CollaborationRevenueReceivable
Namespace Prefix:	rptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaboration term expiration period.

+ References

No definition available.

+ Details

Name:	rptx_CollaborationTermExpirationPeriod
Namespace Prefix:	rptx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration term extended period.

+ References

No definition available.

+ Details

Name:	rptx_CollaborationTermExtendedPeriod
Namespace Prefix:	rptx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Deferred revenue triggered furthur development.

+ References

No definition available.

+ Details

Name:	rptx_DeferredRevenueTriggeredFurthurDevelopment
Namespace Prefix:	rptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Estimated period of completion of trials to get revenue.

+ References

No definition available.

+ Details

Name:	rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue
Namespace Prefix:	rptx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestones payments.

+ References

No definition available.

+ Details

Name:	rptx_MilestonesPayments
Namespace Prefix:	rptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Option fee.

+ References

No definition available.

+ Details

Name:	rptx_OptionFee
Namespace Prefix:	rptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Second amendment agreement.

+ References

No definition available.

+ Details

Name:	rptx_SecondAmendmentAgreement
Namespace Prefix:	rptx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously reported as deferred or unearned revenue.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rptx_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_ClinicalTrialMaterialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_AdditionalClinicalDevelopmentPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_UpfrontNonRefundableFirstPaymentReceivedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_DruggableTargetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_ProductResearchActivityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_ResearchDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreement - Additional Information (Details) $ in Thousands, ¥ in Millions					1 Months Ended						3 Months Ended		6 Months Ended		7 Months Ended
	Oct. 31, 2021 USD ($)	Oct. 31, 2021 JPY (¥)	Jan. 01, 2019 USD ($)	Jan. 01, 2019 JPY (¥)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 JPY (¥)	Jul. 31, 2022	Oct. 31, 2021	Jun. 30, 2020 USD ($)	May 30, 2020	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jul. 31, 2023	Jun. 30, 2023 JPY (¥)	Mar. 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	May 31, 2020 USD ($)
Roche
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											$ 138,626		$ 138,626
Roche \| Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Estimated period of completion of trials to get revenue							24 months
Non-refundable payment received											134,600		134,600
Deferred revenue recognized											4,800	$ 0	10,100	$ 0
Deferred revenue					$ 18,000						11,800		11,800
Deferred revenue, current					15,300						11,100		11,100
Deferred revenue, noncurrent					2,700						700		700
Roche \| Collaboration and License Agreement \| Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Payments													1,172,000
Roche \| Collaboration and License Agreement \| Clinical trial materials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											5,600		5,600
Roche \| Collaboration and License Agreement \| Product additional clinical development plan
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue receivable																		$ 4,000
Non-refundable payment received											4,000		4,000
Amount of additional consideration											4,000		4,000
Roche \| Collaboration and License Agreement \| Upfront non refundable first payment received
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											125,000		125,000
Bristol-Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received											50,000		50,000
Bristol-Myers Squibb Company \| Druggable Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized											12,700	0	12,700	0
Bristol-Myers Squibb Company \| Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration term expiration period										42 months
Initial nonrefundable upfront fee received									$ 50,000
Non-refundable payment received																			$ 50,000
Deferred revenue					27,354						13,287		13,287				$ 26,988
Deferred revenue, current					27,400						13,287		13,287
Deferred revenue, noncurrent											0		0
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Product Research Activity [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized											1,200	700	1,600	1,100
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Druggable Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue, triggered furthur development											1,000	0	1,000	0
Option fee											250		250
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received																			301,000
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Maximum \| Research, Development and Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received																			176,000
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Maximum \| Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received																			$ 125,000
Ono Pharmaceutical Company Ltd \| Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial nonrefundable upfront fee received			$ 8,100	¥ 900
Collaboration term extended period								1 year
Second amendment agreement															In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023
Milestone payments entitled to be received											6,500		6,500			¥ 750
Deferred Revenue, Additions	$ 900	¥ 100			$ 1,500	¥ 200
Deferred revenue recognized											10,500	$ 0	10,500	$ 0
Ono Pharmaceutical Company Ltd \| Collaboration and License Agreement \| Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received											$ 149,500		$ 149,500			¥ 17,210